Clearmind Medicine Inc. (Nasdaq: CMND) announced the completion of treatment for all 24 participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for Alcohol Use Disorder (AUD), according to a press release.

Participants across Cohorts 1 through 4 completed treatment according to the study protocol. The multicenter trial is conducted under FDA oversight at sites including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center in the United States and Israel.

The company said it is currently assessing the dataset and intends to initiate the next stage of the clinical program in AUD patients if results remain favorable.

"We are pleased to have successfully completed treatment for all participants in Part A of the study, fully aligned with the clinical protocol," said Adi Zuloff-Shani, PhD, CEO of Clearmind Medicine. "With data review now underway, we are eager to progress to the next phase of development and continue advancing CMND-100 as a promising therapeutic candidate for Alcohol Use Disorder."

Clearmind describes itself as a clinical-stage biotech company focused on developing non-hallucinogenic, neuroplastogen-derived therapeutics. The company holds a portfolio of 19 patent families, including 32 granted patents.